October 1, 2024 Investor Beware: Port Strike Puts Key Stocks And Sectors At Risk
September 30, 2024 Market Movers: Jobs Report and Key Earnings in Focus
September 19, 2024 Federal Reserve’s Aggressive Move Hints At Bold Economic Strategy
Apple: Lock In Gains Before They Evaporate
Tesla Stock: Too Many Unknowns After Robotaxi Event
Tesla: Time And Patience Running Out
The Biggest Problem With Nvidia’s Stock That Everyone Is Missing
October 3, 2024 Your Path to Profits: The Best Trading Platforms for New Traders
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Abbott Laboratories (ABT) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: October 14, 2024 (19:52)
Sector: HealthcareThe share price of Abbott Laboratories (ABT) now
News Impact Analyzer
Full report|
This Week
|
Bullish | Impact: 5 | News: 2 (1/1/0) |
|
Previous Week
|
Bullish | Impact: 5 | News: 1 (1/0/0) |
|
Two Weeks Ago
|
Bearish | Impact: 5 | News: 1 |
|
Three Weeks Ago
|
Bullish | Impact: 1.14 | News: 5 (1/3/1) |
Analysts predictions
Full report|
This Week
|
Neutral | Opinions: 1 |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Neutral | Opinions: Na |
|
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important ABT news
Netflix Earnings and Oil Market Take Center Stage as Abbott Awaits
Oppenheimer Rates Abbott as Outperform: Diverse Portfolio Fuels Growth
WHO's Mpox Test Approval Could Boost Abbott's Market Position
Historical and forecast chart of Abbott Laboratories stock
The chart below shows the historical price of Abbott Laboratories stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Abbott Laboratories stock price can be found in the table below.
Long-term forecasts by years.
Abbott Laboratories Analysts predictions review
As of now, Panda has combed through 1 analytical articles which are directly related to ABT from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 1 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Oct 14, 2024 to Oct 14, 2024.
Abbott Laboratories: Navigating High Expectations With Premium Valuation in Q3
In this review, we delve into The Alpha Sieve's analytical financial assessment of ABT stock, where the author maintains a Neutral stance. With a significant track record of 589 publications since 2020, The Alpha Sieve demonstrates both dedication and expertise in the financial sector. The author has amassed a substantial following, reflected by an impressive 3,914 subscribers, indicative of the growing popularity and trust in their viewpoints. Based on their metrics, the author possesses high credibility, a testament to the thoughtful analysis and insights that regularly engage a diverse audience. This review offers an opportunity to explore the latest insights from a respected voice known for balanced perspectives in the financial analysis domain.
Key Theses of the Review
- Abbott Laboratories is slated to announce its Q3 results on October 16th, with expectations in line with the Q2 trend.
- The company faces challenging comparables due to last year's double-digit topline growth across all divisions.
- Medical Devices and Diagnostics are the largest divisions, jointly contributing two-thirds to group sales, with a focus on diabetes care and lab diagnostics.
- An increase in share buyback initiatives is anticipated due to low YTD spend and expected cash flow improvements in H2.
- Abbott's stock is viewed as an unattractive rotational opportunity in the large-cap healthcare sector due to its premium valuation and single-digit earnings growth.
Factors Influencing ABT's Stock Price
Q3 Earnings and Revenue Expectations
The anticipation of earnings and revenue growth in line with Q2 could stabilize investor expectations but might not incite enthusiasm or significant stock movement.
Challenging Year-Over-Year Comparables
With last year's robust double-digit growth in all divisions, the current year's comparables set a high benchmark that may suppress perceived growth potential, affecting investor sentiment.
Performance of Medical Devices and Diagnostics Divisions
These divisions are crucial, contributing significantly to sales, particularly through innovative products like FreeStyle Libre, wherein any growth or innovation can directly influence stock valuation.
Share Buyback Initiatives
An expected ramp-up in share buybacks could improve stock sentiment as it signals confidence, but its impact may be limited by current low spending and overall cash flow constraints.
Premium Valuation Related to Historical Averages
ABT's forward P/E ratio trades at a premium to its historical average, which might deter investors seeking value, thus limiting upside potential despite broader market trends.
Review the original Analysis
Abbott Laboratories: Innovating Beyond Challenges for Future Growth
Leo Nelissen, a prolific contributor with over 2,960 publications since 2015, offers an analytical review of ABT stock, maintaining a bullish stance on its potential. With a substantial subscriber base of 34,704, Nelissen's viewpoints are not only popular but also highly credible. His extensive experience and output per year indicate a remarkable commitment to financial analysis. Moreover, his authority in the field is underscored by his excellent credibility rating, emphasizing that his opinions hold significant weight in the financial community. Readers can, therefore, trust that his analysis of ABT stock is both insightful and well-grounded, reflecting a deep understanding of market trends and an anticipation of future growth.
Key Theses of the Article
- Abbott's diversified growth strategy in medical devices and established pharmaceuticals is setting it up for long-term success.
- Despite facing legal challenges and post-pandemic setbacks, Abbott's strong earnings growth and dividend profile make it a compelling investment.
- The company's innovation pipeline, especially in CGM systems, supports its market share expansion and growth outlook.
- While valuation and competition pose risks, Abbott's resilience and adaptability make a bullish outlook justifiable.
Key Factors Influencing Abbott's Stock Price
Diversified Growth Strategy
Abbott's growth driven by a well-diversified product portfolio across medical devices and pharmaceuticals is crucial for market stability. This strategy strengthens its position amid market fluctuations, offering a more predictable revenue flow.
Innovation Pipeline
The advancements in Continuous Glucose Monitoring (CGM) systems and approval of new products like Lingo and Libre Rio are propelling Abbott's growth, contributing to significant revenue and market share gains. The strong innovation pipeline indicates sustained future growth prospects.
Legal Challenges
While Abbott faces numerous lawsuits concerning its infant formula products, analysts believe potential liabilities are marginal, limiting severe financial impact. Such legal issues, though concerning, have not substantially harmed investor confidence to date.
Post-Pandemic Market Adjustments
The decrease in COVID-19 related product sales introduced revenue challenges, yet Abbott's refocus on core growth areas is compensating for these declines. The ongoing adjustments in market demand are expected to balance post-pandemic disruptions.
Valuation Challenges
Abbott's high valuation based on historical P/E ratios poses a risk as market sentiments adjust post-pandemic. However, improved growth and reduced pandemic headwinds could sustain or enhance its market performance.
Review the original Analysis
Commentary
Comprehensive Analysis of Abbott Laboratories (ABT) Stock Market Performance
Our multifaceted analysis of Abbott Laboratories's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Abbott Laboratories stock?
- When should I record a loss on Abbott Laboratories stock?
- What are analysts' forecasts for Abbott Laboratories stock?
- What is the future of Abbott Laboratories stock?
We forecast Abbott Laboratories stock performance using neural networks based on historical data on Abbott Laboratories stocks.
Abbott Laboratories News influencing stock rates
As of now, Panda has combed through 9 news items directly related to ABT from the last 30 days. Out of these, 3 clearly showcase a bullish trend, while 2 display bearish tendencies, and 4 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 1.64 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from Sep 15, 2024, to Oct 11, 2024.
Abbott, Reckitt Face Legal Battle Over Baby Formula Safety Risks
Steady Growth: Abbott Solidifies Investor Confidence with Consistent Dividend
Abbott: Piper Sandler Sees Upside, Labels Stock a Buy
Senseonics Launches World's First Year-Long CGM in US
Moderna Dominates Short Interest: ABT Holds Steady with Minimal Short Activity
Alphabet, Walmart, and L3Harris Lead as Least Shorted S&P 500 Stocks in August
Morocco Confirms First Mpox Case Amid WHO Alert
Applied DNA and Co-Diagnostics Surge on Heightened Government Mpox Measures
Top 50 Defensive Stocks for Bull Steepening Era – Part 1
Abbott's New Lingo Hits Market: A Game Changer in Glucose Monitoring
Abbott Laboratories manufactures drugs, medical devices and diagnostic tools – tests for immunity and blood tests that are used in clinics and hospitals in N countries. The first HIV test was developed by Abbott.
Business publications and major stock indices recognize Abbott Laboratories’ contributions: Fortune magazine has ranked the company as one of the most respected in the world every year since 1984.
The company was founded in 1888. The University of Michigan graduate Wallace Abbott worked as a medical practitioner and opened his own pharmacy. He introduced a new way of using alkaloids of medicinal plants: he formed granules from them with micro doses. Treatment with these granules helped patients because the doses of the drug were accurate and the effect was predictable and consistent.
Abbott Laboratories daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Oct 16 | 116.72 | 116.12 | 118.22 | 1.81 |
| Oct 17 | 117.45 | 116.29 | 117.99 | 1.45 |
| Oct 18 | 117.87 | 116.12 | 118.67 | 2.19 |
| Oct 19 | 118.55 | 116.73 | 119.76 | 2.60 |
| Oct 20 | 118.91 | 118.24 | 120.36 | 1.79 |
| Oct 21 | 119.55 | 118.81 | 121.08 | 1.91 |
| Oct 22 | 119.05 | 118.38 | 120.67 | 1.93 |
| Oct 23 | 118.95 | 117.29 | 120.67 | 2.88 |
| Oct 24 | 119.60 | 118.26 | 120.96 | 2.29 |
| Oct 25 | 118.71 | 118.12 | 119.47 | 1.15 |
| Oct 26 | 119.47 | 118.39 | 120.69 | 1.94 |
| Oct 27 | 118.63 | 117.21 | 120.34 | 2.67 |
| Oct 28 | 118.37 | 117.57 | 119.77 | 1.87 |
| Oct 29 | 118.30 | 117.64 | 119.84 | 1.87 |
| Oct 30 | 118.28 | 116.76 | 119.60 | 2.43 |
| Oct 31 | 118.99 | 118.11 | 120.75 | 2.24 |
| Nov 01 | 120.96 | 120.19 | 121.71 | 1.27 |
| Nov 02 | 120.79 | 118.93 | 122.24 | 2.78 |
| Nov 03 | 121.76 | 121.13 | 122.37 | 1.03 |
| Nov 04 | 119.67 | 117.77 | 121.44 | 3.11 |
| Nov 05 | 120.17 | 118.65 | 121.63 | 2.51 |
| Nov 06 | 120.74 | 119.25 | 122.22 | 2.49 |
| Nov 07 | 120.55 | 119.88 | 122.29 | 2.01 |
| Nov 08 | 120.82 | 119.61 | 121.49 | 1.58 |
| Nov 09 | 121.66 | 121.01 | 122.64 | 1.35 |
| Nov 10 | 120.79 | 119.70 | 121.97 | 1.90 |
| Nov 11 | 121.34 | 120.49 | 122.34 | 1.53 |
| Nov 12 | 122.39 | 121.87 | 123.07 | 0.98 |
| Nov 13 | 120.75 | 119.92 | 122.29 | 1.97 |
| Nov 14 | 119.47 | 118.73 | 120.64 | 1.61 |
Abbott Laboratories Daily Price Targets
Abbott Laboratories Stock Forecast 10-16-2024.
Forecast target price for 10-16-2024: $116.72.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.777%.
Pessimistic target level: 116.12
Optimistic target level: 118.22
Abbott Laboratories Stock Forecast 10-17-2024.
Forecast target price for 10-17-2024: $117.45.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.434%.
Pessimistic target level: 116.29
Optimistic target level: 117.99
Abbott Laboratories Stock Forecast 10-18-2024.
Forecast target price for 10-18-2024: $117.87.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.145%.
Pessimistic target level: 116.12
Optimistic target level: 118.67
Abbott Laboratories Stock Forecast 10-19-2024.
Forecast target price for 10-19-2024: $118.55.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.534%.
Pessimistic target level: 116.73
Optimistic target level: 119.76
Abbott Laboratories Stock Forecast 10-20-2024.
Forecast target price for 10-20-2024: $118.91.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.758%.
Pessimistic target level: 118.24
Optimistic target level: 120.36
Abbott Laboratories Stock Forecast 10-21-2024.
Forecast target price for 10-21-2024: $119.55.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.876%.
Pessimistic target level: 118.81
Optimistic target level: 121.08
ABT (ABT) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Nov. | 113.24 | 108.35 | 119.13 | 9.05 |
| Dec. | 117.95 | 112.67 | 120.12 | 6.21 |
Abbott Laboratories forecast for this year
Abbott Laboratories Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $113.24. Pessimistic: $108.35. Optimistic: $119.13
Abbott Laboratories Stock Prediction for Dec 2024
An uptrend is forecast for this month with an optimal target price of $117.951. Pessimistic: $112.67. Optimistic: $120.12
Abbott Laboratories (ABT) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 114.65 | 112.63 | 119.14 | 5.47 |
| Feb | 117.31 | 112.24 | 119.56 | 6.12 |
| Mar | 115.34 | 112.57 | 121.70 | 7.51 |
| Apr | 114.23 | 108.20 | 116.70 | 7.28 |
| May | 118.16 | 111.07 | 125.63 | 11.59 |
| Jun | 114.57 | 107.60 | 117.50 | 8.42 |
| Jul | 113.56 | 109.11 | 117.83 | 7.40 |
| Aug | 121.01 | 118.40 | 123.04 | 3.78 |
| Sep | 122.66 | 115.98 | 126.38 | 8.23 |
| Oct | 118.34 | 110.86 | 122.22 | 9.30 |
| Nov | 127.80 | 121.57 | 133.84 | 9.17 |
| Dec | 122.79 | 115.82 | 127.90 | 9.45 |
Abbott Laboratories (ABT) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 121.32 | 118.41 | 125.79 | 5.86 |
| Feb | 131.03 | 128.09 | 137.21 | 6.65 |
| Mar | 131.24 | 127.56 | 133.86 | 4.71 |
| Apr | 127.25 | 120.22 | 133.25 | 9.78 |
| May | 136.31 | 129.87 | 140.01 | 7.24 |
| Jun | 128.02 | 125.25 | 135.80 | 7.77 |
| Jul | 121.26 | 115.44 | 128.63 | 10.26 |
| Aug | 118.06 | 110.50 | 125.24 | 11.76 |
| Sep | 119.57 | 112.59 | 122.73 | 8.26 |
| Oct | 121.77 | 119.43 | 124.98 | 4.44 |
| Nov | 126.54 | 122.29 | 129.58 | 5.63 |
| Dec | 132.21 | 129.57 | 139.51 | 7.13 |
Abbott Laboratories information and performance
100 ABBOTT PARK ROAD, ABBOTT PARK, IL, US
Market capitalization of the Abbott Laboratories is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ABT shares in the company outstanding by the market price of one share.
EBITDA of Abbott Laboratories is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Abbott Laboratories (ABT) stock dividend
Abbott Laboratories last paid dividends on 10/15/2024. The next scheduled payment will be on 11/15/2024. The amount of dividends is $2.16 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Commentary
In anticipation of Abbott Laboratories' upcoming Q3 results on October 16th, the stakes are set high. The company is grappling with tough comparables from last year's impressive growth across all divisions, setting a daunting benchmark that may temper investor enthusiasm. Medical Devices and Diagnostics divisions stand out as pivotal areas, influencing two-thirds of the sales with continued innovations like FreeStyle Libre. However, these factors, along with anticipated earnings and revenue in line with Q2, create a neutral outlook as they seem to balance each other out, hinting at limited stock movement in the short term.
Further adding to the complexity is Abbott's premium valuation, which might suppress investor interest eager for value, despite the prospect of increased share buybacks signaling corporate confidence. The weighted influence, examining both the average strength and relevance of these factors over the next 15 to 30 days, suggests a cautious stance. Combined, these factors reinforce a neutral trajectory for Abbott’s stock trend, indicating a period of wait-and-see among investors as they assess the company's ability to meet or surpass market expectations amid high standards.